Patients using ICSs during GL@ , but only using ICSs @ % to @ % of the time during GL@ ( n = @ of @ ) , had significantly accelerated annual FEV@ decline compared with GL@ ( difference GL@-GL@ -LSB- @ % CI -RSB- : @-month treatment with fluticasone and salmeterol , -@ mL/y -LSB- -@ to -@ -RSB- , P = @ ; @-month treatment with fluticasone , -@ mL/y -LSB- -@ to -@ -RSB- , P = @ ) , accompanied by deterioration in AHR and QOL .